Creating a monoclonal antibody to reverse fentanyl overdoses
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
This study is working on a new treatment that uses a special antibody to help people who have overdosed on fentanyl, aiming to quickly remove the drug from their system and prevent serious breathing problems, while also looking at how it can be used with other medications for those struggling with opioid use.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10615519 on NIH RePORTER |
What this research studies
This research focuses on developing a humanized monoclonal antibody that can effectively treat and reverse the toxic effects of fentanyl and its analogs in overdose situations. The approach involves manufacturing the antibody and conducting preclinical studies to assess its pharmacokinetics, efficacy, and safety before moving to clinical trials. By selectively sequestering fentanyl from circulation, this treatment aims to prevent respiratory depression and other life-threatening symptoms associated with overdose. The research team is also exploring how this antibody can be used alongside existing medications for opioid use disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk of fentanyl overdose, such as those with opioid use disorders.
Not a fit: Patients who are not at risk for opioid overdose or those who do not use opioids may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for reversing fentanyl overdoses, potentially saving lives.
How similar studies have performed: Other research has shown promise in using monoclonal antibodies for drug overdose treatment, indicating potential success for this novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Pravetoni, Marco — University of Washington
- Study coordinator: Pravetoni, Marco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.